Home > Neurology > ECTRIMS 2021 > Treatment Trials and Strategies > Ublituximab meets primary endpoint for relapsing MS

Ublituximab meets primary endpoint for relapsing MS

Presented By
Prof. Lawrence Steinman, Stanford University, CA, USA
Conference
ECTRIMS 2021
Trial
Phase 3, ULTIMATE I, ULTIMATE II
Ublituximab was more efficacious than teriflunomide in patients with relapsing MS. Annualised relapse rates and MRI parameters demonstrated superiority of ublituximab over teriflunomide. These results, along with a favourable safety profile, showed that ublituximab has the potential to become the first 1-hour anti-CD20 infusion therapy in relapsing MS patients [1]. Prof. Lawrence Steinman (Stanford University, CA, USA) presented the 96-week results of the identical phase 3, randomised, multicentre, double-blind ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) trials. Subjects with relapsing MS (n=549, n=545) were randomised 1:1 to 450 mg intravenous ublituximab every 24 weeks or 14 mg oral teriflunomide once daily. The primary endpoint was the annualised relapse rate ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on